| Literature DB >> 35127923 |
He-Xiao Tang1, Li Zhang2, Yan-Hong Wei3, Chang-Sheng Li1, Bo Hu4, Jing-Ping Zhao1, Nahush A Mokadam5, Hua Zhu5, Jun Lin6, Su-Fang Tian7, Xue-Feng Zhou8.
Abstract
BACKGROUND: The corona virus disease 2019 (COVID-19) has been a pandemic for more than one year and estimated to affect the whole world in the near future. CASEEntities:
Keywords: Case report; Corona Virus Disease 2019; Pulmonary vesicle; Surgical treatment
Year: 2022 PMID: 35127923 PMCID: PMC8790432 DOI: 10.12998/wjcc.v10.i3.1086
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Perioperative laboratory tests on patient underwent surgery. A: Perioperative blood routine results showed that COVID-19 patient with pulmonary vesicles showed higher rate of infections, fewer platelets, more neutrophils and fewer lymphocytes. B: After receiving surgery, the TLC and I/CLC in the patient’s circulating blood showed a “W-shaped” curve, NK cells and BLC showed an “M-shaped” curve, H/I LC showed a trend of increasing gradually, and cytoknes (IL-2, 4, 6, 10, Interferon γ, TNF α) showed an upward trend as a whole. C: The level of circulating estrogen was higher than the normal range, while the level of ACE was in the normal range. The COVID-19 patient with pulmonary vesicles showed varying degrees of liver and kidney damage, mild body temperature elevation, and large changes in fluid intake and output. D: 20 d before bullectomy, the chest CT scans of the patient showed changes in small vesicles in the lung. E: Chest X-ray, before bullectomy. F: Chest X-ray, after bullectomy. G: The pulmonary vesicles of the patient during the bullectomy. H: A common pulmonary bulla. NR: Normal range; PCT: Procalcitonin; TLC: T lymphocyte; BLC: B lymphocyte; I/CLC: Inhibition/cytotoxic T lymphocytes; NK cells: Natural killer cells; H/I LC: Helper/inducible T lymphocytes.